Tenosynovial giant cell tumor of the ankle: a clinical case

Background. Tenosynovial giant cell tumor is a rare benign disease that primarily affects the synovium and tendon sheath. Its prevalence is 30.3 cases per million people per year. Surgery remains the primary treatment for tenosynovial giant cell tumor. Tumor excision is the gold standard of treatment; however, along with the tumor, compromised areas of the tendon sheath, capsule, and ligamentous apparatus should be excised, which can cause joint dysfunction. Therefore, careful preoperative planning is essential for tenosynovial giant cell tumor. This includes not only determining the extent of tumor resection but also reconstructing the ligamentous component to restore range of motion and preserve the function of the operated joint.

The aim. To present a clinical case of surgical treatment of tenosynovial giant cell tumor with simultaneous resection of the tumor and additional stabilization of the ankle joint using the Brostrom – Gould technique.

Materials and methods. 65-year-old woman was admitted with a diagnosis of tenosynovial giant cell tumor of the left ankle, grade II osteoarthritis of the left ankle, and regional osteoporosis. After thorough preoperative preparation, the patient underwent surgical treatment: excision of the tumor and ligament reconstruction of the ankle.

Conclusion. In our clinical case, the tumor was completely removed, and the surgery was carried out along with ankle stabilization. Over a one-year follow-up, the patient has shown no signs of tumor recurrence, and ankle function and ability to work have been fully restored.

1. Khodorkovsky MA, Skorynin OS, Vasiliev NO, Kalashnik OS. Experience in surgical treatment of patients with pigmented villonodular synovitis of the tendon sheaths of the fingers. Proceedings of the XXIII Congress of the I.P. Pavlov Physiological Society with international participation (Voronezh, September 18–22, 2017). Voronezh: Istoki; 2017: 2585-2587. (In Russ.).

2. Yotsuya K, Shido Y, Matsuyama Y. Invasion patterns and long-term clinical outcomes of diffuse tenosynovial giant cell tumor of the ankle joint. Cureus. 2024; 16(3): e56148. doi: 10.7759/cureus.56148

3. Ipponi E, Ruinato AD, Lombardi L, Cordoni M, Franco S, D’Arienzo A, et al. Outcomes of surgical treatment for localized tenosynovial giant-cell tumor of the foot and ankle: A case series. Acta Med Litu. 2023; 30(2): 163170. doi: 10.15388/Amed.2023.30.2.8

4. Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R, et al. Tenosynovial giant cell tumor: Incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017; 44: 1476-1483. doi: 10.3899/jrheum.160816

5. Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: An international, retrospective, cohort study. Lancet Oncol. 2019; 20(6): 877-886. doi: 10.1016/ S1470-2045(19)30100-7

6. Fraser EJ, Sullivan M, Maclean F, Nesbitt A. Tenosynovial giant-cell tumors of the foot and ankle: A critical analysis review. JBJS Rev. 2017; 5(1): 1874474–20170100000001. doi: 10.2106/JBJS.RVW.16.00025

7. Chou LB, Ho YY, Malawer MM. Tumors of the foot and ankle: Experience with 153 cases. Foot Ankle Int. 2009; 30(9): 836-841. doi: 10.3113/fai.2009.0836

8. Siegel M, Bode L, Südkamp N, Kühle J, Zwingmann J, Schmal H, et al. Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle – A systematic review and meta-analysis. PLoS One. 2021; 16(12): e0260795. doi: 10.1371/journal.pone.0260795

9. Scheele C, Harrasser N, Beischl S, Dammerer D, Lenze U, Knebel C, et al. Tenosynovial giant cell tumours of the foot and ankle: A retrospective single centre experience with surgical treatment of 34 cases. BMC Cancer. 2025; 25(1): 530. doi: 10.1186/s12885-025-13921-7